Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume 73, Issue 5, Pages 755-757
Publisher
Oxford University Press (OUP)
Online
2021-08-20
DOI
10.1093/cid/ciab718
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes
- (2020) Alice Y. Guh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study
- (2020) Richard L Hengel et al. Open Forum Infectious Diseases
- Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
- (2019) Carlos Rubio-Terrés et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland
- (2019) Jarmo Oksi et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials
- (2019) Sarah E. Madoff et al. ANAEROBE
- Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
- (2019) Zachariah DeFilipp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
- (2018) Dale N Gerding et al. CLINICAL INFECTIOUS DISEASES
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
- (2018) L Clifford McDonald et al. CLINICAL INFECTIOUS DISEASES
- Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting
- (2018) Simon W. Lam et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection
- (2018) Thomas Birch et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness
- (2018) Oliver A Cornely et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of fidaxomicin for the treatment of Clostridioides ( Clostridium ) difficile infection in a randomized, double-blind, comparative Phase III study in Japan
- (2018) Hiroshige Mikamo et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Is pulsed dosing the answer to treatment of Clostridium difficile infection?
- (2018) Dale N Gerding LANCET INFECTIOUS DISEASES
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
- (2018) Benoit Guery et al. LANCET INFECTIOUS DISEASES
- Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain
- (2018) Miguel Salavert et al. ADVANCES IN THERAPY
- Population pharmacokinetics and pharmacodynamics of bezlotoxumab in adults with primary and recurrent Clostridium difficile infection
- (2018) Ka Lai Yee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
- (2017) Mark H. Wilcox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile -Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation
- (2017) Kelly R. Reveles et al. PHARMACOTHERAPY
- A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
- (2016) Maureen Watt et al. INFECTION
- Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire
- (2016) Kevin W. Garey et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection
- (2016) Lauren Lapointe-Shaw et al. PLoS One
- Clinical and Healthcare Burden of Multiple Recurrences ofClostridium difficileInfection
- (2015) Caroline Sheitoyan-Pesant et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model
- (2015) C. H. Chilton et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies
- (2014) M. M. Soriano et al. Open Forum Infectious Diseases
- Is Fidaxomicin Worth the Cost? An Economic Analysis
- (2013) Sarah M. Bartsch et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- (2012) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Antimicrobial Activities of Fidaxomicin
- (2012) Ellie J. C. Goldstein et al. CLINICAL INFECTIOUS DISEASES
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
- (2012) O. A. Cornely et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- (2010) Stuart H. Cohen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search